Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Malaria Treatment Market Snapshot (2023 to 2033)

The global malaria treatment market is expected to be worth US$ 1.8 Billion in the fiscal year 2023, up from US$ 1.72 Billion in the fiscal year 2022. From 2023 to 2033, the market is expected to grow at a 5% CAGR, reaching a value of US$ 2.93 Billion by the end of 2033.

Malaria is described by the World Intellectual Property Organization (WIPO) as an infectious, potentially fatal disease that impacted more than 210 million people worldwide in 2019. It is brought on by a small parasite called Plasmodium, which mosquitoes spread to people. There are four distinct Plasmodium species that may cause malaria, but Plasmodium falciparum is the one that results in fatal cases.

Malaria patients often experience fever, headache, vomiting, as well as shivering, but more severe instances can also present with symptoms including severe anemia, breathing difficulties, organ failure, and nervous system issues. To detect the presence of the disease and keep an eye out for relapses, a variety of diagnostic procedures can be used, including thick blood smears, fast antigen tests, molecular tests, antibody tests, and susceptibility tests.

The bulk of malaria infections and malaria death, according to a November 2019 paper by the American Association for Clinical Chemistry (AACC), occur in Africa. In addition to this, instances have also been documented in the South Pacific, Eastern Europe, the Middle East, Central and South America, South Asia, and portions of the Caribbean. In addition, the World Health Organization (WHO) estimated 585,000 malaria-related fatalities globally in 2013, mostly in children from Africa.

Government attention on COVID-19 therapy is becoming more and more important, which will help the industry expand soon. The governments of the nations where COVID-19 cases have been reported have encouraged India to expand its hydroxychloroquine exports. For instance, according to a recent news report, the United States government acquired nine metric tonnes of the active pharmaceutical ingredients (API) needed to manufacture drugs, as well as about 3.52 million tablets of hydroxychloroquine. Additionally, a significant number of businesses producing hydroxychloroquine in India will support market expansion in the years to come. Over 1.5 million pills may be produced every day by the two major companies, Ipca Laboratories, and Zydus Cadila. As a result, the aforementioned variables will promote market expansion.

Attributes Details
Anticipated Base Year Value (2022) US$ 1.72 Billion
Expected Market Value (2023) US$ 1.80 Billion
Projected Forecast Value (2033) US$ 2.93 Billion
Global Growth Rate (2023 to 2033) 5%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Malaria Treatment Market Demand Analysis Vs. Forecast 2023 to 2033

The global malaria treatment market grew at a CAGR of 3.2% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence. One of the key drivers of the global market expansion for antimalarial medications was the exponential rise of COVID-19 infections.

For instance, the World Health Organization recently released statistics showing that there were approximately 1.8 million recorded incidents of coronavirus illness worldwide. Chloroquine can stop a virus from infecting individuals because they have the capacity to alter the acidity at the cell's surface. As a result, it was determined that the COVID-19 virus will be inhibited by tablets containing hydroxychloroquine. A rise in COVID-19 cases worldwide and the possibility of treating malaria with hydroxychloroquine led to successful malaria treatment and prevention.

Even in areas with low incomes, the use of these medications is growing due to their cost-effectiveness. Chloroquine, a widely used and cost-effective medication, costs roughly 10 cents for each adult treatment course. Additionally, each round of treatment with the artemisinin combination therapy (ACT) costs $2.4. Due to its low cost, malaria medicine is widely accessible and is anticipated to experience rapid acceptance in the near future. Such steps will boost the demand for malaria treatment globally during the forecast period.

Prominent Growth Drivers Influencing Malaria Treatment Market

Collaboration among the top players and increased Research and Development efforts are anticipated to fuel market expansion

The mission of the Medicines for Malaria Venture (MMV), a non-profit public-private collaboration founded in 1999, is to lessen the impact of malaria in nations where the illness is endemic by creating new treatment alternatives. The development of new drug entities for the treatment of malaria has been a focus of collaboration between MMV and several of the major pharmaceutical firms. For instance, in December 2019, Ipca Laboratories and Medicines for Malaria Venture collaborated to create Atoguanil, a new antimalarial co-formulation that combines atovaquone as well as proguanil.

The market for anti-malaria medications worldwide is also expanding dramatically as a result of increased financing from regional governments. These funds should allow research organizations like Medicines for Malaria Venture to continue their investigations into possible malaria-fighting lead compounds. For instance, the USA Agency for International Development (USAID) provided funding of US$ 9 million to Medicines for Malaria Venture in November 2017 for the purpose of conducting three projects, including a pharmacovigilance study of Pyramax (pyronaridine-artesunate), a SERC Phase III research to establish a single-exposure revolutionary cure, as well as a study to assess the efficacy of DSM265, a prospective single-exposure radical cure. Such developments are expected to be driving the market for malaria treatment worldwide.

Increased Government Initiatives and Measures to boost Demand

This market is expanding as a result of increased government awareness campaigns and research into new antimalarial medications and treatments. For instance, the antimalarial medication ZY19489 (MMV253) being developed by Medicines for Malaria Venture was granted orphan drug classification by the USA Food and Drug Administration in December 2021. (MMV). Additionally, according to news reports from March 2021, researchers from the Francis Crick Institute and the Latvian Institute of Organic Synthesis have created a drug-like compound that successfully blocks a crucial stage in the life cycle of the malaria parasite.

The market will expand as a result of increased research into the creation of anti-malarial medications, which will result in the release of novel molecules for anti-malarial therapy and an increase in consumer adoption. Additionally, according to the report, the Malawian government began the Zero Malaria Starts with Me campaign in June 2021 with the goal of eradicating malaria by the year 2030. Malaria is the primary cause of death in Malawi and accounts for 15% of hospital admissions there. Thus, during the projection period, it is predicted that the global market for malaria treatment would grow as a result of such initiatives globally.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What Could Possibly Hinder Malaria Treatment Market Demand?

Adverse side effects and drug resistance issues will hinder the market growth

The limited supply of anti-malarial medications and the escalating resistance issues in many regions of the world have made it more challenging to establish antimalarial treatment strategies, which has hampered the expansion of the malaria treatment market. The frequency of parasite mutation, the extent of resistance imparted by the genetic change, the concentration and temperature profile of the drugs, the sequence of drug use, as well as the percentage of all transmissible infections exposed to the drug are the factors that affect the development of antibiotic resistance, according to an article published by the Institute of Medicine (USA) Committee on the Economics of Antimalarial Drugs.

Since the majority of anti-malaria medications have serious adverse effects, there should be less demand for them. Mefloquine, for instance, can cause vomiting, nausea, headaches, stomachaches, sleeplessness, and vivid nightmares. Mefloquine is also known to have certain additional adverse effects, including lightheadedness, loss of balance, extreme anxiety, sadness, restlessness, disorientation, and others. Such elements are predicted to impede market expansion from 2023 to 2033.

Region-wise Analysis

What is the outlook for the North American Malaria Treatment Market?

Increased usage of Hydroxychloroquine to propel Regional Demand

With a CAGR of 4.6% from 2023 to 2033, the North American region is anticipated to considerably contribute to the malaria treatment market growth during the research period.

In the near future, it is projected that the USA antimalarial medicine industry would dominate. The country's steadily increasing coronavirus illness instances will favorably affect the market's expansion. The COVID-19 infection may be treated with hydroxychloroquine, according to the USA Food and Drug Administration. For instance, hydroxychloroquine is now being studied on more than 1,500 individuals in New York who have the coronavirus, according to a recent news piece. Therefore, hydroxychloroquine could become necessary in the future as a result of this. The USA market for antimalarial medications will also rise as a result of the import of hydroxychloroquine tablets.

What can be expected from the MEA market for Malaria Treatment?

Rising Incidences of Malaria will boost the demand during the Forecast Period

Throughout the anticipated period, Asia Pacific exhibits a significant market potential for malaria treatment. According to the Future Market Insights projections, the market will grow with a steady CAGR of 5.5% from 2023 to 2033 and will exhibit the fastest CAGR during the forecast period.

Due to the rapidly increasing frequency of malaria in the area, the Middle East and Africa have held the lion's share of the market share and are predicted to do so going forward. The World Health Organization (WHO) report 2021 states that there were an expected 241 million cases of malaria globally in 2020, with 228 million of those cases occurring in the WHO African Region. As a result, it is anticipated that the Middle East and Africa would account for one of the greatest portions of the market for anti-malarial drugs.

Additionally, growing efforts from African businesses on the local level to produce anti-malarial medications and approvals from international regulatory bodies would increase the acceptance of these drugs in this area, spurring market expansion. For instance, Kenyan producer Universal Corporation Ltd (UCL) has been given permission by the World Health Organization to help local efforts to eliminate malaria by producing high-quality sulfadoxine-pyrimethamine starting in August 2022. (SP) Such activities will increase local manufacture of anti-malarial medications, which will increase sales and fuel market expansion in this region. The market is thus anticipated to have considerable expansion as a result of the quickest growth caused by the rise in knowledge regarding the usage of antimalarial medications for early detection of infection.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Which is likely to be the most preferred Route of Administration for Malaria Drugs?

Oral Malarial Drug Administration to remain Popular across the Forecast Period

In 2022, the oral route of administration category had a bigger market share, and in 2023, it is anticipated to take 49% of the market. Additionally, it is also predicted that throughout the projection period, the same category would see a higher CAGR of 4.9%.

The benefits of safety, ease of ingesting, improved patient compliance, pain prevention, and adaptability to accept different types of medications are credited with the segmental expansion. Additionally, as hydroxychloroquine is only available as tablets, the requirement for oral administrations will increase during the course of the projection period, helping those who have been infected by the coronavirus. Such factors are expected to boost segmental growth during the forecast period.

Which distribution channel segment will be used for these products more often?

Hospital Pharmacies are the most utilized Distribution Channel for procuring Malaria Treatment Drugs

The hospital pharmacies segment will be the fastest-growing segment during the forecast period with a 5.4% CAGR. In the year 2023, this segment is predicted to acquire almost 41% of the market share.

The demand for medications from hospitals directly increases when a sudden epidemic, like malaria, breaks out. This is mainly because customers are aware, hospitals will supply the appropriate medication for the patient's condition.

The hospital pharmacy provides care teams the chance to work together to enhance patient outcomes. Additionally, it prevents prescription mistakes from happening when patients switch from one retail pharmacy to another after being discharged. Therefore, during the course of the predicted period, these benefits will fuel segmental growth.

Start-up Scenario

Startups with greater research funding and distribution networks have made an impact on the industry. The rise of a few minor businesses in the Asia-Pacific region has aided market expansion and raised the level of competition.

  • A biotech start-up with headquarters in Portland, DesignMedix focuses on infectious illnesses that are serious worldwide. At Portland State University, it is jointly developing DM1157, its main candidate for the treatment of malaria. DesignMedix got a $3 Billion grant in April 2023 to continue working on DM1157; this was the third award the business has received in recent years.

Competitive Landscape

Some of the prominent players in the global malaria treatment market are Zydus Healthcare Ltd, Sun Pharmaceutical Industries Ltd., Sanofi SA, GSK Plc, Novartis AG, Cipla Ltd, Viatris Inc., Lupin Ltd, AdvaCare Pharma USA Llc, and VLP Therapeutics Llc.

Some of the prominent developments of the key players in the market are:

  • In July 2022, the Gates Foundation-funded Gavi vaccination project debuted the Mosquirix vaccine, created by GlaxoSmithKline (GSK), in three African nations: Kenya, Ghana, and Malawi. This vaccine is reportedly the first antimalarial vaccine ever produced. This is a crucial first step in the rollout of the malaria vaccine in nations with moderate to high P. falciparum malaria transmission rates. It is the first prequalification for a malaria vaccine.
  • Tafenoquine, a novel medication that treats a specific strain of malaria, was licensed in Australia in March 2022 by Medicines for Malaria Venture (MMV), which co-developed the medication with GlaxoSmithKline (GSK) for children and adolescents. The medication is combined with the widely used antimalarial medicine chloroquine.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 1.8 Billion
Market Value in 2033 US$ 2.93 Billion
Growth Rate CAGR of 5% from 2023 to 2033
Historical Data Available For 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Billion and CAGR from 2023 to 2033
Key Segments Covered
  • Treatment
  • Drug Type
  • Route of Administration
  • Distribution Channel
  • End User
  • Region
Key Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia & Pacific
  • East Asia
  • Middle East & Africa
Key Countries Covered
  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • Australia
  • New Zealand
  • China
  • Japan
  • South Korea
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Zydus Healthcare Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Sanofi SA
  • GSK Plc.
  • Novartis AG
  • Cipla Ltd.
  • Viatris Inc.
  • Lupin Ltd.
  • Advacare Pharma USA LLC
  • VLP Therapeutics LLC
Customization & Pricing Available upon Request

Key Segments Covered in the Malaria Treatment Market Report

Malaria Treatment Market by Treatment:

  • Prescription Medications
  • Vaccines
  • Diagnostic Tests
  • Others

Malaria Treatment Market by Drug Type:

  • Branded
  • Generic

Malaria Treatment Market by Route of Administration:

  • Oral and Parenteral
  • Intravenous

Malaria Treatment Market by Distribution Channel:

  • Direct Tender
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Malaria Treatment Market by End User:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Malaria Treatment Market by Region:

  • North America
  • Europe
  • South Asia and the Pacific
  • East Asia
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

At what rate did the malaria treatment market flourish from 2018 to 2022?

During the historical period of 2018 to 2022, the malaria treatment market grew at a CAGR of 3.2%.

What will be the growth rate of the global malaria treatment market during the forecast period?

The global malaria treatment market is predicted to rise with a steady 5% CAGR from 2023 to 2033.

What is the present market value of the malaria treatment market?

The global malaria treatment market is currently worth more than US$ 1.72 Billion.

What will be the projected market size of the malaria treatment market by 2033?

By 2033, the global malaria treatment market is projected to reach a market size of US$ 2.93 Billion

Which segment is expected to dominate the global malaria treatment market during 2023?

The oral segment by route of administration is going to occupy a 49% global market share in 2023.

What will be the outlook of the other segment during the forecast period?

The hospital pharmacies segment by distribution channel type will be the fastest-growing segment during the forecast period with a 5.4% CAGR.

How is the North American malaria treatment market projected to grow during 2023 to 2033?

The North American region is predicted to grow with a steady CAGR of 4.6% from 2023 to 2033.

What is the outlook of the MEA malaria treatment market during 2023?

The MEA malaria treatment market is expected to grow with a steady CAGR of 5.5% from 2023 to 2033.

Table of Content

1. Executive Summary | Malaria Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

        5.3.1. Prescription Medications

            5.3.1.1. Chloroquine Phospate

            5.3.1.2. ACTs

            5.3.1.3. Atovaquone-Proguanil

            5.3.1.4. Primaquine Phosphate

            5.3.1.5. Other Prescription Medication

        5.3.2. Vaccines

        5.3.3. Other Treatments

    5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033

        6.3.1. Branded

        6.3.2. Generic

    6.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033

        7.3.1. Oral

        7.3.2. Parenteral and Intravenous

    7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        8.3.1. Direct Tender

        8.3.2. Hospital Pharmacies

        8.3.3. Retail Pharmacies

        8.3.4. Online Pharmacies

        8.3.5. Others

    8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    9.1. Introduction / Key Findings

    9.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        9.3.1. Hospitals

        9.3.2. Speciality Clinics

        9.3.3. Homecare

        9.3.4. Other

    9.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    9.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    10.1. Introduction

    10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. South Asia & Pacific

        10.3.5. East Asia

        10.3.6. Middle East and Africa(MEA)

    10.4. Market Attractiveness Analysis By Region

11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. USA

            11.2.1.2. Canada

        11.2.2. By Treatment

        11.2.3. By Drug Type

        11.2.4. By Route of Administration

        11.2.5. By Distribution Channel

        11.2.6. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment

        11.3.3. By Drug Type

        11.3.4. By Route of Administration

        11.3.5. By Distribution Channel

        11.3.6. By End User

    11.4. Key Takeaways

12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Brazil

            12.2.1.2. Mexico

            12.2.1.3. Rest of Latin America

        12.2.2. By Treatment

        12.2.3. By Drug Type

        12.2.4. By Route of Administration

        12.2.5. By Distribution Channel

        12.2.6. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment

        12.3.3. By Drug Type

        12.3.4. By Route of Administration

        12.3.5. By Distribution Channel

        12.3.6. By End User

    12.4. Key Takeaways

13. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Germany

            13.2.1.2. United Kingdom

            13.2.1.3. France

            13.2.1.4. Spain

            13.2.1.5. Italy

            13.2.1.6. Rest of Europe

        13.2.2. By Treatment

        13.2.3. By Drug Type

        13.2.4. By Route of Administration

        13.2.5. By Distribution Channel

        13.2.6. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Treatment

        13.3.3. By Drug Type

        13.3.4. By Route of Administration

        13.3.5. By Distribution Channel

        13.3.6. By End User

    13.4. Key Takeaways

14. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. India

            14.2.1.2. Malaysia

            14.2.1.3. Singapore

            14.2.1.4. Thailand

            14.2.1.5. Australia

            14.2.1.6. New Zealand

            14.2.1.7. Rest of South Asia & Pacific

        14.2.2. By Treatment

        14.2.3. By Drug Type

        14.2.4. By Route of Administration

        14.2.5. By Distribution Channel

        14.2.6. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Treatment

        14.3.3. By Drug Type

        14.3.4. By Route of Administration

        14.3.5. By Distribution Channel

        14.3.6. By End User

    14.4. Key Takeaways

15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. China

            15.2.1.2. Japan

            15.2.1.3. South Korea

        15.2.2. By Treatment

        15.2.3. By Drug Type

        15.2.4. By Route of Administration

        15.2.5. By Distribution Channel

        15.2.6. By End User

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Treatment

        15.3.3. By Drug Type

        15.3.4. By Route of Administration

        15.3.5. By Distribution Channel

        15.3.6. By End User

    15.4. Key Takeaways

16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. South Africa

            16.2.1.3. Israel

            16.2.1.4. Rest of Middle East and Africa(MEA)

        16.2.2. By Treatment

        16.2.3. By Drug Type

        16.2.4. By Route of Administration

        16.2.5. By Distribution Channel

        16.2.6. By End User

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Treatment

        16.3.3. By Drug Type

        16.3.4. By Route of Administration

        16.3.5. By Distribution Channel

        16.3.6. By End User

    16.4. Key Takeaways

17. Key Countries Market Analysis

    17.1. USA

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2022

            17.1.2.1. By Treatment

            17.1.2.2. By Drug Type

            17.1.2.3. By Route of Administration

            17.1.2.4. By Distribution Channel

            17.1.2.5. By End User

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2022

            17.2.2.1. By Treatment

            17.2.2.2. By Drug Type

            17.2.2.3. By Route of Administration

            17.2.2.4. By Distribution Channel

            17.2.2.5. By End User

    17.3. Brazil

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2022

            17.3.2.1. By Treatment

            17.3.2.2. By Drug Type

            17.3.2.3. By Route of Administration

            17.3.2.4. By Distribution Channel

            17.3.2.5. By End User

    17.4. Mexico

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2022

            17.4.2.1. By Treatment

            17.4.2.2. By Drug Type

            17.4.2.3. By Route of Administration

            17.4.2.4. By Distribution Channel

            17.4.2.5. By End User

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2022

            17.5.2.1. By Treatment

            17.5.2.2. By Drug Type

            17.5.2.3. By Route of Administration

            17.5.2.4. By Distribution Channel

            17.5.2.5. By End User

    17.6. United Kingdom

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2022

            17.6.2.1. By Treatment

            17.6.2.2. By Drug Type

            17.6.2.3. By Route of Administration

            17.6.2.4. By Distribution Channel

            17.6.2.5. By End User

    17.7. France

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2022

            17.7.2.1. By Treatment

            17.7.2.2. By Drug Type

            17.7.2.3. By Route of Administration

            17.7.2.4. By Distribution Channel

            17.7.2.5. By End User

    17.8. Spain

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2022

            17.8.2.1. By Treatment

            17.8.2.2. By Drug Type

            17.8.2.3. By Route of Administration

            17.8.2.4. By Distribution Channel

            17.8.2.5. By End User

    17.9. Italy

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2022

            17.9.2.1. By Treatment

            17.9.2.2. By Drug Type

            17.9.2.3. By Route of Administration

            17.9.2.4. By Distribution Channel

            17.9.2.5. By End User

    17.10. India

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2022

            17.10.2.1. By Treatment

            17.10.2.2. By Drug Type

            17.10.2.3. By Route of Administration

            17.10.2.4. By Distribution Channel

            17.10.2.5. By End User

    17.11. Malaysia

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2022

            17.11.2.1. By Treatment

            17.11.2.2. By Drug Type

            17.11.2.3. By Route of Administration

            17.11.2.4. By Distribution Channel

            17.11.2.5. By End User

    17.12. Singapore

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2022

            17.12.2.1. By Treatment

            17.12.2.2. By Drug Type

            17.12.2.3. By Route of Administration

            17.12.2.4. By Distribution Channel

            17.12.2.5. By End User

    17.13. Thailand

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2022

            17.13.2.1. By Treatment

            17.13.2.2. By Drug Type

            17.13.2.3. By Route of Administration

            17.13.2.4. By Distribution Channel

            17.13.2.5. By End User

    17.14. China

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2022

            17.14.2.1. By Treatment

            17.14.2.2. By Drug Type

            17.14.2.3. By Route of Administration

            17.14.2.4. By Distribution Channel

            17.14.2.5. By End User

    17.15. Japan

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2022

            17.15.2.1. By Treatment

            17.15.2.2. By Drug Type

            17.15.2.3. By Route of Administration

            17.15.2.4. By Distribution Channel

            17.15.2.5. By End User

    17.16. South Korea

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2022

            17.16.2.1. By Treatment

            17.16.2.2. By Drug Type

            17.16.2.3. By Route of Administration

            17.16.2.4. By Distribution Channel

            17.16.2.5. By End User

    17.17. Australia

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2022

            17.17.2.1. By Treatment

            17.17.2.2. By Drug Type

            17.17.2.3. By Route of Administration

            17.17.2.4. By Distribution Channel

            17.17.2.5. By End User

    17.18. New Zealand

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2022

            17.18.2.1. By Treatment

            17.18.2.2. By Drug Type

            17.18.2.3. By Route of Administration

            17.18.2.4. By Distribution Channel

            17.18.2.5. By End User

    17.19. GCC Countries

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2022

            17.19.2.1. By Treatment

            17.19.2.2. By Drug Type

            17.19.2.3. By Route of Administration

            17.19.2.4. By Distribution Channel

            17.19.2.5. By End User

    17.20. South Africa

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2022

            17.20.2.1. By Treatment

            17.20.2.2. By Drug Type

            17.20.2.3. By Route of Administration

            17.20.2.4. By Distribution Channel

            17.20.2.5. By End User

    17.21. Israel

        17.21.1. Pricing Analysis

        17.21.2. Market Share Analysis, 2022

            17.21.2.1. By Treatment

            17.21.2.2. By Drug Type

            17.21.2.3. By Route of Administration

            17.21.2.4. By Distribution Channel

            17.21.2.5. By End User

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Treatment

        18.3.3. By Drug Type

        18.3.4. By Route of Administration

        18.3.5. By Distribution Channel

        18.3.6. By End User

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. Zydus Healthcare Ltd

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

        19.1.2. Sun Pharmaceutical Industries Ltd.

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

        19.1.3. Sanofi SA

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

        19.1.4. GSK Plc

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

        19.1.5. Novartis AG

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

        19.1.6. Cipla Ltd

            19.1.6.1. Overview

            19.1.6.2. Product Portfolio

            19.1.6.3. Profitability by Market Segments

            19.1.6.4. Sales Footprint

            19.1.6.5. Strategy Overview

                19.1.6.5.1. Marketing Strategy

        19.1.7. Viatris Inc.

            19.1.7.1. Overview

            19.1.7.2. Product Portfolio

            19.1.7.3. Profitability by Market Segments

            19.1.7.4. Sales Footprint

            19.1.7.5. Strategy Overview

                19.1.7.5.1. Marketing Strategy

        19.1.8. Lupin Ltd

            19.1.8.1. Overview

            19.1.8.2. Product Portfolio

            19.1.8.3. Profitability by Market Segments

            19.1.8.4. Sales Footprint

            19.1.8.5. Strategy Overview

                19.1.8.5.1. Marketing Strategy

        19.1.9. Advacare Pharma USA LLC

            19.1.9.1. Overview

            19.1.9.2. Product Portfolio

            19.1.9.3. Profitability by Market Segments

            19.1.9.4. Sales Footprint

            19.1.9.5. Strategy Overview

                19.1.9.5.1. Marketing Strategy

        19.1.10. VLP Therapeutics LLC

            19.1.10.1. Overview

            19.1.10.2. Product Portfolio

            19.1.10.3. Profitability by Market Segments

            19.1.10.4. Sales Footprint

            19.1.10.5. Strategy Overview

                19.1.10.5.1. Marketing Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Recommendations

Services and Utilities

Mosquito Repellent Candles Market

Published : July 2023

Healthcare

Dengue Vaccines Market

Published : May 2023

Explore Healthcare Insights

View Reports